10,916 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP acquired a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,916 shares of the biopharmaceutical company’s stock, valued at approximately $459,000.

A number of other large investors have also recently bought and sold shares of RARE. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $83,000. Principal Financial Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 740.0% during the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after purchasing an additional 76,150 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Ultragenyx Pharmaceutical by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company’s stock valued at $1,658,000 after purchasing an additional 3,246 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after purchasing an additional 294 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of Ultragenyx Pharmaceutical by 2,275.8% during the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock worth $2,567,000 after buying an additional 58,442 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on RARE shares. Wedbush reaffirmed a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Piper Sandler dropped their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Monday, March 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $92.79.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $38.09 on Friday. The company has a market capitalization of $3.58 billion, a PE ratio of -6.01 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The company has a 50 day simple moving average of $37.79 and a two-hundred day simple moving average of $43.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Activity

In related news, CAO Theodore Alan Huizenga sold 967 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares in the company, valued at $2,116,156.50. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the sale, the executive vice president now owns 265,238 shares of the company’s stock, valued at $11,166,519.80. The trade was a 2.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock valued at $5,256,268 in the last ninety days. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.